10 results on '"Aguirre-Hernandez, Rosalia"'
Search Results
2. Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome
- Author
-
Tessier-Cloutier, Basile, Pors, Jennifer, Thompson, Emily, Ho, Julie, Prentice, Leah, McConechy, Melissa, Aguirre-Hernandez, Rosalia, Miller, Ruth, Leung, Samuel, Proctor, Lily, McAlpine, Jessica N., Huntsman, David G., Gilks, C. Blake, and Hoang, Lynn N.
- Published
- 2021
- Full Text
- View/download PDF
3. The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis.
- Author
-
McGuire, Anna L., McConechy, Melissa K., Melosky, Barb L., English, John C., Choi, James J., Peng, Defen, Yee, John, Furman, Benjamin L. S., Aguirre Hernandez, Rosalia, Feijao, Pedro, Mulder, David, Hughesman, Curtis, and Yip, Stephen
- Subjects
MOLECULAR probes ,NON-small-cell lung carcinoma ,BIOMARKERS ,PALLIATIVE treatment ,TISSUES - Abstract
Background: Despite meticulous surgery for non-small cell lung cancer (NSCLC), relapse is as high as 70% at 5 years. Many institutions do not conduct reflexive molecular testing on early stage specimens, although targeted gene therapy may extend life by years in the event of recurrence. This ultimately delays definitive treatment with additional biopsy risking suboptimal tissue acquisition and quality for molecular testing. Objective: To compare molecular profiles of genetic alterations in early and late NSCLC to provide evidence that reflexive molecular testing provides clinically valuable information. Methods: A single-center propensity matched retrospective analysis was conducted using prospectively collected data. Adults with early and late-stage NSCLC had tissue subject to targeted panel-based NGS. Frequencies of putative drivers were compared, with 1:3 matching on the propensity score; p < 0.05 deemed statistically significant. Results: In total, 635 NSCLC patients underwent NGS (59 early, 576 late); 276 (43.5%) females; age 70.9 (±10.2) years; never smokers 140 (22.0%); 527 (83.0%) adenocarcinomas. Unadjusted frequencies of EGFR mutations were higher in the early cohort (30% vs. 18%). Following adjustment for sex and smoking status, similar frequencies for both early and late NSCLC were observed for variants in EGFR, KRAS, ALK, MET, and ROS1. Conclusion: The frequency of clinically actionable variants in early and late-stage NSCLC was found to be similar, providing evidence that molecular profiling should be performed on surgical specimens. This pre-determined profile is essential to avoid treatment delay for patients who will derive clinical benefit from targeted systemic therapy, in the high likelihood of subsequent relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. β2-Adrenergic Receptor Gene Polymorphism Is Associated with Mortality in Septic Shock
- Author
-
Nakada, Taka-aki, Russell, James A., Boyd, John H., Aguirre-Hernandez, Rosalia, Thain, Katherine R., Thair, Simone A., Nakada, Emiri, McConechy, Melissa, and Walley, Keith R.
- Published
- 2010
- Full Text
- View/download PDF
5. Initial association of NR2E1 with bipolar disorder and identification of candidate mutations in bipolar disorder, schizophrenia, and aggression through resequencing
- Author
-
Kumar, Ravinesh A., McGhee, Kevin A., Leach, Stephen, Bonaguro, Russell, Maclean, Alan, Aguirre-Hernandez, Rosalia, Abrahams, Brett S., Coccaro, Emil F., Hodgins, Sheilagh, Turecki, Gustavo, Condon, Anne, Muir, Walter J., Brooks-Wilson, Angela R., Blackwood, Douglas H., and Simpson, Elizabeth M.
- Published
- 2008
- Full Text
- View/download PDF
6. Oncogenic mutations in histologically normal endometrium: the new normal?
- Author
-
Lac, Vivian, Nazeran, Tayyebeh M, Tessier‐Cloutier, Basile, Aguirre‐Hernandez, Rosalia, Albert, Arianne, Lum, Amy, Khattra, Jaswinder, Praetorius, Teresa, Mason, Madeline, Chiu, Derek, Köbel, Martin, Yong, Paul J, Gilks, Blake C, Anglesio, Michael S, and Huntsman, David G
- Subjects
GENETIC mutation ,ENDOMETRIUM ,SOMATIC mutation ,ENDOMETRIOSIS ,ENDOMETRIAL cancer ,EPITHELIUM ,ENDOMETRIAL hyperplasia - Abstract
The advent of next generation sequencing has vastly improved the resolution of mutation detection, thereby both increasing the resolution of the analysis of cancer tissues and shining light on the existence of somatic driver mutations in normal tissues, even in the absence of cancer. Studies have described somatic driver mutations in normal skin, blood, peritoneal washings, and esophageal epithelium. Such findings prompt speculation on whether such mutations exist in other tissues, such as the eutopic endometrium in particular, due to the highly regenerative nature of the endometrium and the recent observation of recurrent somatic driver mutations in deep infiltrating and iatrogenic endometriosis (tissues believed to be derived from the eutopic endometrium) by our group and others. In the current study we investigated the presence of somatic driver mutations in histologically normal endometrium from women lacking evidence of gynecologic malignancy or endometrial hyperplasia. Twenty‐five women who underwent hysterectomies and 85 women who underwent endometrial biopsies were included in this study. Formalin‐fixed, paraffin‐embedded tissue specimens were analyzed by means of targeted sequencing followed by orthogonal validation with droplet digital PCR. PTEN and ARID1A immunohistochemistry (IHC) was also performed as surrogates for inactivating mutations in the respective genes. Overall, we observed somatic driver‐like events in over 50% of normal endometrial samples analyzed, including hotspot mutations in KRAS, PIK3CA, and FGFR2 as well as PTEN‐loss by IHC. Analysis of anterior and posterior samplings collected from women who underwent hysterectomies was consistent with the presence of somatic driver mutations within clonal pockets spread throughout the uterus. The prevalence of such oncogenic mutations also increased with age (OR: 1.05 [95% CI: 1.00–1.10], p = 0.035). These findings have implications on our understanding of aging and so‐called 'normal tissues', thereby necessitating caution in the utilization of mutation‐based early detection tools for endometrial or other cancers. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
- Author
-
Prentice, Leah M., Miller, Ruth R., Knaggs, Jeff, Mazloomian, Alborz, Aguirre Hernandez, Rosalia, Franchini, Patrick, Parsa, Kourosh, Tessier-Cloutier, Basile, Lapuk, Anna, Huntsman, David, Schaeffer, David F., and Sheffield, Brandon S.
- Subjects
FORMALDEHYDE ,DEAMINATION ,COLON cancer treatment ,GENETIC mutation ,POLYMERASE chain reaction - Abstract
Genomic analysis of cancer tissues is an essential aspect of personalized oncology treatment. Though it has been suggested that formalin fixation of patient tissues may be suboptimal for molecular studies, this tissue processing approach remains the industry standard. Therefore clinical molecular laboratories must be able to work with formalin fixed, paraffin embedded (FFPE) material. This study examines the effects of pre-analytic variables introduced by routine pathology processing on specimens used for clinical reports produced by next-generation sequencing technology. Tissue resected from three colorectal cancer patients was subjected to 2, 15, 24, and 48 hour fixation times in neutral buffered formalin. DNA was extracted from all tissues twice, once with uracil-N-glycosylase (UNG) treatment to counter deamination effects, and once without. Of note, deamination events at methylated cytosine, as found at CpG sites, remains unaffected by UNG. After extraction a two-step PCR targeted sequencing method was performed using the Illumina MiSeq and the data was analyzed via a custom-built bioinformatics pipeline, including filtration of reads with mapping quality <30. A larger baseline group of samples (n = 20) was examined to establish if there was a sample performance difference between the two DNA extraction methods, with/without UNG treatment. There was no statistical difference between sequencing performance of the two extraction methods when comparing read counts (raw, mapped, and filtered) and read quality (% mapped, % filtered). Analyzing mutation type, there was no significant difference between mutation calls until the 48 hour fixation treatment. At 48 hours there is a significant increase in C/G->T/A mutations that is not represented in DNA treated with UNG. This suggests these errors may be due to deamination events triggered by a longer fixation time. However the allelic frequency of these events remained below the limit of detection for reportable mutations in this assay (<2%). We do however recommend that suspected intratumoral heterogeneity events be verified by re-sequencing the same FFPE block. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.
- Author
-
Jamieson, Amy, Huvila, Jutta, Thompson, Emily F., Leung, Samuel, Chiu, Derek, Lum, Amy, McConechy, Melissa, Grondin, Katherine, Aguirre-Hernandez, Rosalia, Salvador, Shannon, Kean, Sarah, Samouelian, Vanessa, Gougeon, Francois, Azordegan, Nazila, Lytwyn, Alice, Parra-Herran, Carlos, Offman, Saul, Gotlieb, Walter, Irving, Julie, and Kinloch, Mary
- Subjects
- *
ENDOMETRIAL cancer , *GENETIC testing , *ENDOMETRIAL surgery , *ADJUVANT chemotherapy , *HEALTH equity , *HEREDITARY nonpolyposis colorectal cancer , *COMPUTED tomography - Abstract
We measured the variation in practice across all aspects of endometrial cancer (EC) management and assessed the potential impact of implementation of molecular classification. Centers from across Canada provided representative tumor samples and clinical data, including preoperative workup, operative management, hereditary cancer program (HCP) referrals, adjuvant therapy, surveillance and outcomes, for all EC patients diagnosed in 2016. Tumors were classified into the four ProMisE molecular subtypes. A total of 1336 fully evaluable EC patients were identified from 10 tertiary cancer centers (TC; n = 1022) and 19 community centers (CC; n = 314). Variation of surgical practice across TCs was profound (14–100%) for lymphadenectomy (LND) (mean 57% Gr1/2, 82% Gr3) and omental sampling (20% Gr1/2, 79% Gr3). Preoperative CT scans were inconsistently obtained (mean 32% Gr1/2, 51% Gr3) and use of adjuvant chemo or chemoRT in high risk EC ranged from 0–55% and 64–100%, respectively. Molecular subtyping was performed retrospectively and identified 6% POLE mut, 28% MMRd, 48% NSMP and 18% p53abn ECs, and was significantly associated with survival. Within patients retrospectively diagnosed with MMRd EC only 22% had been referred to HCP. Of patients with p53abn EC, LND and omental sampling was not performed in 21% and 23% respectively, and 41% received no chemotherapy. Comparison of management in 2016 with current 2020 ESGO/ESTRO/ESP guidelines identified at least 26 and 95 patients that would have been directed to less or more adjuvant therapy, respectively (10% of cohort). Molecular classification has the potential to mitigate the profound variation in practice demonstrated in current EC care, enabling reproducible risk assessment, guiding treatment and reducing health care disparities. • Characterization of National practice in EC reveals profound variation in workup, surgery, treatment, and genetic testing. • Molecular classification identified missed opportunities for EC patients managed by traditional risk stratification. • Both overtreatment (POLE mut given adjuvant therapy) and undertreatment (p53abn not given chemo or any therapy) were exposed. • Only 22% retrospectively identified MMRd ECs had been referred for genetic testing with <4% confirmed to have Lynch Syndrome. • Molecular classification can objectively categorize ECs, direct treatment, and has the potential to reduce practice variation and disparities. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment.
- Author
-
Zaikova E, Cheng BYC, Cerda V, Kong E, Lai D, Lum A, Bates C, den Brok W, Kono T, Bourque S, Chan A, Feng X, Fenton D, Gurjal A, Levasseur N, Lohrisch C, Roberts S, Shenkier T, Simmons C, Taylor S, Villa D, Miller R, Aguirre-Hernandez R, Aparicio S, and Gelmon K
- Abstract
Circulating tumour DNA (ctDNA) detection via liquid biopsy is an emerging alternative to tissue biopsy, but its potential in treatment response monitoring and prognosis in triple negative breast cancer (TNBC) is not yet well understood. Here we determined the prevalence of actionable mutations detectable in ctDNA using a clinically validated cancer gene panel assay in patients with TNBC, without recurrence at the time of study entry. Sequencing of plasma DNA and validation of variants from 130 TNBC patients collected within 7 months of primary treatment completion revealed that 7.7% had detectable residual disease with a hotspot panel. Among neoadjuvant treated patients, we observed a trend where patients with incomplete pathologic response and positive ctDNA within 7 months of treatment completion were at much higher risk of reduced progression free survival. We propose that a high risk subset of early TNBC patients treated in neoadjuvant therapy protocols may be identifiable by combining tissue response and sensitive ctDNA detection., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock.
- Author
-
Nakada TA, Russell JA, Boyd JH, Aguirre-Hernandez R, Thain KR, Thair SA, Nakada E, McConechy M, and Walley KR
- Subjects
- Adrenergic alpha-Agonists therapeutic use, Adult, Aged, British Columbia, Cells, Cultured drug effects, Child, Cohort Studies, Double-Blind Method, Gene Frequency genetics, Genotype, Haplotypes, Humans, Infant, Interleukin-6 antagonists & inhibitors, Linkage Disequilibrium, Middle Aged, Norepinephrine therapeutic use, Phenotype, Polymorphism, Single Nucleotide genetics, Risk Factors, Shock, Septic drug therapy, Vasoconstrictor Agents therapeutic use, Vasopressins therapeutic use, Alleles, Polymorphism, Genetic genetics, Receptors, Adrenergic, beta-2 genetics, Shock, Septic genetics, Shock, Septic mortality
- Abstract
Rationale: The CysGlyGln haplotype of the beta(2)-adrenergic receptor gene (ADRB2) is functional and associated with altered responses to adrenergic agonists in patients with asthma. Whether this functional haplotype alters outcome in patients receiving adrenergic agonists in septic shock is unknown., Objectives: To determine whether genetic variation of ADRB2 influences outcome in septic shock., Methods: Two cohorts of patients with septic shock were studied: a single center (St. Paul's Hospital [SPH]) cohort (n = 589) and the Vasopressin and Septic Shock Trial (VASST) cohort (n = 616). The A allele of the rs1042717 G/A polymorphism is in complete linkage disequilibrium with the CysGlyGln haplotype of ADRB2; therefore, rs1042717 was genotyped. Modulation by norepinephrine and salbutamol of IL-6 production by stimulated in vitro lymphoblastoid cells was measured by genotype., Measurements and Main Results: Patients who had the AA genotype of rs1042717 displayed increased 28-day mortality in SPH (adjusted hazard ratio, 2.23; 95% confidence interval, 1.33-3.72; P = 0.0022), and this result was replicated in VASST (adjusted hazard ratio 2.82; 95% confidence interval, 1.56-5.09; P = 0.0006). This genotypic effect was eliminated in patients treated with acute low-dose corticosteroids. In all patients, the AA genotype was associated with more organ dysfunction. Patients with the AA genotype had a higher heart rate (SPH; P < 0.05; VASST; P < 0.05) and required a higher norepinephrine dose over Days 1 through 3 (VASST; P < 0.05). The AA genotype was associated with decreased norepinephrine and salbutamol inhibition of IL-6 production by stimulated lymphoblastoid cells in vitro (P < 0.05)., Conclusions: The AA genotype of ADRB2 rs1042717, identifying homozygotes for the CysGlyGln haplotype, was associated with increased mortality and more organ dysfunction in septic shock.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.